Showing Results for
- Academic Journals (9)
Search Results
- 9
Academic Journals
- 9
- Search Terms:ISSN: 09291903AndISSN: 14765500AndVolume Number: 16AndIssue Number: 3AndStart Page: 195AndDate: 2009 Revise Search
- 1From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedWe examined the microRNA (miRNA) expression profile of 40 prostatectomy specimens from stage T2a/b, early relapse and nonrelapse cancer patients, to better understand the relationship between miRNA dysregulation and...
- 2From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedRecombinant oncolytic viruses represent a promising alternative option for the treatment of malignant cancers. We have reported earlier the safety and efficacy of recombinant vesicular stomatitis virus (VSV) vectors in a...
- 3From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedCancer is a complex disease involving multiple oncogenes with diverse actions. Inhibiting only one oncogene is unlikely to eliminate the malignancy of cancer cells. The goal of this study was to investigate whether...
- 4From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedLiposomes are a useful means of delivering molecular targeting agents such as small interfering RNA (siRNA) to downregulate specific pathways important in cancer growth and progression. The ability to non-invasively...
- 5From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedCombining the use of a chemotherapeutic agent with oncolytic virotherapy is a useful way to increase the efficiency of the treatment of cancer. The effect of the histone diacetylase (HDAC) inhibitor trichostatin A (TSA)...
- 6From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedRecent studies have demonstrated the efficacy of targeted therapy combined with radiotherapy in head and neck squamous cell carcinoma (HNSCC). We hypothesized that a combination treatment including a replicating...
- 7From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedDifferent routes for the in vivo administration of synthetic siRNA complexes targeting lung tumors were compared, and siRNA complexes were administered for the inhibition of hypoxia-inducible factor (HIF-1 α and HIF-2α)....
- 8From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedThe future success of cancer gene therapy is critically dependent upon the development of safe, practical and effective targeting strategies. In this study, we describe a novel and broadly applicable targeting approach...
- 9From: Cancer Gene Therapy. (Vol. 16, Issue 3) Peer-ReviewedThe fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this...